Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Business Wire
Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk’s FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and delivery methods. This expansion makes Hims & Hers the largest global consumer health platform for affordable access to approved medications.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326503294/en/Starting today, eligible customers can access a broad assortment of treatment options, including the
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health (HIMS) had its price target lowered by TD Cowen from $25.00 to $23.00. They now have a "hold" rating on the stock.MarketBeat
- Surging Oil Prices Spark Market Jitters [Yahoo! Finance]Yahoo! Finance
- HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire
- INSP vs. HIMS: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
- Hims & Hers (HIMS) Tumbles 8.86% on Market Bloodbath, Profit-Taking [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 2/23/26 - Beat
HIMS
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/24/26 - Form 4
- 3/18/26 - Form 4
- HIMS's page on the SEC website